Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study

被引：0

作者：

Wolin, Edward M. ^{[1
]}

Pavel, Marianne E. ^{[2
]}

Cwikla, Jaroslaw B. ^{[3
]}

Phan, Alexandria T. ^{[4
]}

Raderer, Markus ^{[5
]}

Sedlackova, Eva ^{[6
,7
]}

Cadiot, Guillaume ^{[8
]}

Capdevila, Jaume ^{[9
]}

Wall, Lucy ^{[10
]}

Rindi, Guido ^{[11
]}

Lombard-Bohas, Catherine ^{[12
]}

Liyanage, Nilani ^{[13
]}

Thanh, Xuan-Mai Truong ^{[14
]}

Ruszniewski, Philippe B. ^{[15
]}

Caplin, Martyn E. ^{[16
]}

Investigators, Clarinet ^{[17
]}

机构：

[1] Montefiore Einstein Ctr Canc Care, New York, NY USA

[2] Univ Klinikum Erlangen, Erlangen, Germany

[3] Univ Warmia & Mazury, Olsztyn, Poland

[4] Canc Treatment Ctr Amer, Atlanta, GA USA

[5] Univ Hosp, Vienna, Austria

[6] First Fac Med, Prague, Czech Republic

[7] Gen Teaching Hosp, Prague, Czech Republic

[8] Robert Debre Hosp, Reims, France

[9] Vall dHebron Univ Hosp, Barcelona, Spain

[10] Western Gen Hosp, Edinburgh, Midlothian, Scotland

[11] Univ Cattolica Sacro Cuore, Rome, Italy

[12] Hosp Civils Lyon, Edouard Herriot Hosp, Lyon, France

[13] Ipsen, Les Ulis, France

[14] Ipsen, Boulogne, France

[15] Beaujon Hosp, Clichy, France

[16] Royal Free Hosp, London, England

[17] CLARINET Study Investigators, London, England

来源：

PANCREAS | 2018年 / 47卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：358 / 359

页数：2

共 50 条

[31] Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study.
Wolin, Edward M.
Caplin, Martyn E.
Pavel, Marianne E.
Cwikla, Jaroslaw B.
Phan, Alexandria T.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Capdevila, Jaume
Wall, Lucy
Rindi, Guido
Langley, Alison
Gomez-Panzani, Edda
Ruszniewski, Philippe B.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[32] Health-Related Quality of Life (HRQoL) with Lanreotide Autogel (LAN) 120 mg in Patients with Enteropancreatic (EP-)NETs: Post Hoc Analyses from the CLARINET Study
Caplin, M.
Pavel, M.
Cwikla, J. B.
Phan, A. T.
Raderer, M.
Sedlackova, E.
Cadiot, G.
Wolin, E. M.
Capdevila, J.
Wall, L.
Rindi, G.
Langley, A.
Gomez-Panzani, E.
Ruszniewski, P. B.
NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 123 - 123
[33] Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged ≤65 vs. >65 years: Subgroup analyses from the CLARINET study.
Dasari, A.
Phan, Alexandria T.
Caplin, Martyn E.
Pavel, Marianne E.
Cwikla, Jaroslaw B.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Wolin, Edward M.
Capdevila, Jaume
Wall, Lucy
Rindi, Guido
Langley, Alison
Gomez-Panzani, Edda
Ruszniewski, Philippe B.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[34] Long-term safety/tolerability of lanreotide autogel/depot (LAN) treatment for metastatic intestinal and pancreatic neuroendocrine tumours (NETs): Final results of the CLARINET open-label extension (OLE)
Caplin, M.
Pavel, M.
Cwikla, J. C.
Phan, A.
Raderer, M.
Sedlackova, E.
Cadiot, G.
Wolin, E.
Capdevila, J.
Wall, L.
Rindi, G.
Liyanage, N.
Braun, S.
Ruszniewski, P.
ANNALS OF ONCOLOGY, 2016, 27
[35] Exploratory analysis of tumor growth rate (TGR) with lanreotide depot/autogel (LAN) in patients (pts) with neuroendocrine tumors (NETs) from the CLARINET study
Caplin, Martyn E.
Pavel, Marianne E.
Ruszniewski, Philippe
Liyanage, Nilani
Massien, Christine
Dromain, Clarisse
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[36] Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study.
Phan, Alexandria T.
Caplin, Martyn E.
Pavel, Marianne E.
Cwikla, Jaroslaw B.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Wolin, Edward M.
Capdevila, Jaume
Wall, Lucy
Rindi, Guido
Langley, Alison
Gomez-Panzani, Edda
Ruszniewski, Philippe B.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[37] Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
Pusceddu, Sara
Prinzi, Natalie
Tafuto, Salvatore
Ibrahim, Toni
Filice, Angelina
Brizzi, Maria Pia
Panzuto, Francesco
Baldari, Sergio
Grana, Chiara M.
Campana, Davide
Davi, Maria Vittoria
Giuffrida, Dario
Zatelli, Maria Chiara
Partelli, Stefano
Razzore, Paola
Marconcini, Riccardo
Massironi, Sara
Gelsomino, Fabio
Faggiano, Antongiulio
Giannetta, Elisa
Bajetta, Emilio
Grimaldi, Franco
Cives, Mauro
Cirillo, Fernando
Perfetti, Vittorio
Corti, Francesca
Ricci, Claudio
Giacomelli, Luca
Porcu, Luca
Di Maio, Massimo
Seregni, Ettore
Maccauro, Marco
Lastoria, Secondo
Bongiovanni, Alberto
Versari, Annibale
Persano, Irene
Rinzivillo, Maria
Pignata, Salvatore Antonio
Rocca, Paola Anna
Lamberti, Giuseppe
Cingarlini, Sara
Puliafito, Ivana
Ambrosio, Maria Rosaria
Zanata, Isabella
Bracigliano, Alessandra
Severi, Stefano
Spada, Francesca
Andreasi, Valentina
Modica, Roberta
Scalorbi, Federica
JAMA NETWORK OPEN, 2022, 5 (02)
[38] Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results
Pavel, M.
Cwikla, J. B.
Lombard-Bohas, C.
Borbath, I
Shah, T.
Pape, U. F.
Thanh, Truong X. M.
Houchard, A.
Ruszniewski, P.
JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 143 - 143
[39] Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Phan, Alexandria T.
Dasari, Arvind
Liyanage, Nilani
Cox, David
Lowenthal, Susan Pitman
Wolin, Edward M.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[40] Texture analysis in the prediction of progression-free survival (PFS) in patients with progressive neuroendocrine tumors (NETs) treated with lanreotide autogel (LAN) in the prospective, open-label, non-comparative, phase 2 CLARINET FORTE trial
Dromain, C.
Thanh, Truong X. M.
Grandoulier, A. S.
Pavel, M.
JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 138 - 138

← 1 2 3 4 5 →